Raymond James initiated coverage of Rapport Therapeutics (RAPP) with a Strong Buy rating and $66 price target
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RAPP:
- Rapport Therapeutics initiated with a Strong Buy at Raymond James
- Advancing RAP-219: Phase 3 Progress, 2026 Catalysts, and Strategic China Partnership Support a Buy Rating
- Rapport Therapeutics files automatic mixed securities shelf
- Rapport Therapeutics reports Q4 EPS (72c), consensus (67c)
- Rapport Therapeutics sees cash runway into 2H29